Targeting polyamine metabolism

A viable therapeutic/preventative solution for cancer?

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The polyamine pathway has been identified as a target for the design of new antiproliferative drugs, due to the strong positive relationship between intracellular polyamine content and cell, particularly cancer cell growth. A number of single enzyme inhibitors have been synthesised against the two key biosynthetic enzymes, ornithine decarboxylase and S-adenosylmethionine decarboxylase, but their success in the clinic has been limited due to incomplete polyamine depletion and induction of compensatory mechanisms that counteract the effects of enzyme inhibition. Overall, clinical trials of these agents as chemotherapeutic drugs have proved disappointing, with either little clinical efficacy or unacceptable toxicity. The polyamine analogues provide an alternative strategy that shows promise, particularly against diseases other than cancer. Combination of the polyamine inhibitors with classic cytotoxic agents may be an alternative strategy that is showing some promise, at least in vitro. An avenue that is, however, presently more promising is the use of polyamine inhibitors or analogues as chernopreventative agents against a range of human cancers. It seems likely that the future use of these drugs will be in disease prevention rather than treatment. With regard to the newer agents with restricted conformation that are now undergoing clinical trials, it is too early to say whether they will be chemotherapeutic and/or chernopreventative. This article focuses on the clinical use and responses to inhibitors of polyamine metabolism.

Original languageEnglish
Pages (from-to)2109-2116
Number of pages8
JournalExpert Opinion on Pharmacotherapy
Volume8
Issue number13
DOIs
Publication statusPublished - Sep 2007

Keywords

  • cancer prevention
  • enzyme inihibitors
  • polyamine
  • adenosylmethionine decarboxylase inhibitor
  • cervical intraepithelial neoplasia
  • alpha-difluoromethylornithine
  • phase-I
  • breast-cancer
  • antitumor-activity
  • human prostate
  • ornithine decarboxylase
  • solid tumors
  • cell-death

Cite this

Targeting polyamine metabolism : A viable therapeutic/preventative solution for cancer? / Wallace, Heather M.

In: Expert Opinion on Pharmacotherapy, Vol. 8, No. 13, 09.2007, p. 2109-2116.

Research output: Contribution to journalArticle

@article{7384a498d9b74ee18796cc6ee247d58a,
title = "Targeting polyamine metabolism: A viable therapeutic/preventative solution for cancer?",
abstract = "The polyamine pathway has been identified as a target for the design of new antiproliferative drugs, due to the strong positive relationship between intracellular polyamine content and cell, particularly cancer cell growth. A number of single enzyme inhibitors have been synthesised against the two key biosynthetic enzymes, ornithine decarboxylase and S-adenosylmethionine decarboxylase, but their success in the clinic has been limited due to incomplete polyamine depletion and induction of compensatory mechanisms that counteract the effects of enzyme inhibition. Overall, clinical trials of these agents as chemotherapeutic drugs have proved disappointing, with either little clinical efficacy or unacceptable toxicity. The polyamine analogues provide an alternative strategy that shows promise, particularly against diseases other than cancer. Combination of the polyamine inhibitors with classic cytotoxic agents may be an alternative strategy that is showing some promise, at least in vitro. An avenue that is, however, presently more promising is the use of polyamine inhibitors or analogues as chernopreventative agents against a range of human cancers. It seems likely that the future use of these drugs will be in disease prevention rather than treatment. With regard to the newer agents with restricted conformation that are now undergoing clinical trials, it is too early to say whether they will be chemotherapeutic and/or chernopreventative. This article focuses on the clinical use and responses to inhibitors of polyamine metabolism.",
keywords = "cancer prevention, enzyme inihibitors, polyamine, adenosylmethionine decarboxylase inhibitor, cervical intraepithelial neoplasia, alpha-difluoromethylornithine, phase-I, breast-cancer, antitumor-activity, human prostate, ornithine decarboxylase, solid tumors, cell-death",
author = "Wallace, {Heather M.}",
year = "2007",
month = "9",
doi = "10.1517/14656566.8.13.2109",
language = "English",
volume = "8",
pages = "2109--2116",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "13",

}

TY - JOUR

T1 - Targeting polyamine metabolism

T2 - A viable therapeutic/preventative solution for cancer?

AU - Wallace, Heather M.

PY - 2007/9

Y1 - 2007/9

N2 - The polyamine pathway has been identified as a target for the design of new antiproliferative drugs, due to the strong positive relationship between intracellular polyamine content and cell, particularly cancer cell growth. A number of single enzyme inhibitors have been synthesised against the two key biosynthetic enzymes, ornithine decarboxylase and S-adenosylmethionine decarboxylase, but their success in the clinic has been limited due to incomplete polyamine depletion and induction of compensatory mechanisms that counteract the effects of enzyme inhibition. Overall, clinical trials of these agents as chemotherapeutic drugs have proved disappointing, with either little clinical efficacy or unacceptable toxicity. The polyamine analogues provide an alternative strategy that shows promise, particularly against diseases other than cancer. Combination of the polyamine inhibitors with classic cytotoxic agents may be an alternative strategy that is showing some promise, at least in vitro. An avenue that is, however, presently more promising is the use of polyamine inhibitors or analogues as chernopreventative agents against a range of human cancers. It seems likely that the future use of these drugs will be in disease prevention rather than treatment. With regard to the newer agents with restricted conformation that are now undergoing clinical trials, it is too early to say whether they will be chemotherapeutic and/or chernopreventative. This article focuses on the clinical use and responses to inhibitors of polyamine metabolism.

AB - The polyamine pathway has been identified as a target for the design of new antiproliferative drugs, due to the strong positive relationship between intracellular polyamine content and cell, particularly cancer cell growth. A number of single enzyme inhibitors have been synthesised against the two key biosynthetic enzymes, ornithine decarboxylase and S-adenosylmethionine decarboxylase, but their success in the clinic has been limited due to incomplete polyamine depletion and induction of compensatory mechanisms that counteract the effects of enzyme inhibition. Overall, clinical trials of these agents as chemotherapeutic drugs have proved disappointing, with either little clinical efficacy or unacceptable toxicity. The polyamine analogues provide an alternative strategy that shows promise, particularly against diseases other than cancer. Combination of the polyamine inhibitors with classic cytotoxic agents may be an alternative strategy that is showing some promise, at least in vitro. An avenue that is, however, presently more promising is the use of polyamine inhibitors or analogues as chernopreventative agents against a range of human cancers. It seems likely that the future use of these drugs will be in disease prevention rather than treatment. With regard to the newer agents with restricted conformation that are now undergoing clinical trials, it is too early to say whether they will be chemotherapeutic and/or chernopreventative. This article focuses on the clinical use and responses to inhibitors of polyamine metabolism.

KW - cancer prevention

KW - enzyme inihibitors

KW - polyamine

KW - adenosylmethionine decarboxylase inhibitor

KW - cervical intraepithelial neoplasia

KW - alpha-difluoromethylornithine

KW - phase-I

KW - breast-cancer

KW - antitumor-activity

KW - human prostate

KW - ornithine decarboxylase

KW - solid tumors

KW - cell-death

U2 - 10.1517/14656566.8.13.2109

DO - 10.1517/14656566.8.13.2109

M3 - Article

VL - 8

SP - 2109

EP - 2116

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 13

ER -